001), while in a landmark analysis, survival was associated with NT-proBNP reduction of ≥ 30% ( P =. Baseline NT-proBNP was independently associated with survival ( P =. Median survival has not been reached and the 1-year survival rate is 76%. After a median follow-up of 12 months, 29% of patients had organ progression and 27% had hematologic progression. Hematologic responses were associated with a cardiac response and NT-proBNP reduction. A cardiac response was documented in 29% of patients, in most as sustained improvement of functional class and less often as a decrease in wall thickness. 041) were associated with higher response rates. 043) and twice weekly administration of bortezomib ( P =. Previously untreated patients had a 47% CR rate.
A hematologic response was achieved in 71% within a median of 52 days, including 25% complete responses (CRs).
0 kommentar(er)
